Dolby Laboratories Inc
For the period ended Mar 29, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 29, 2024 · Filed May 2, 2024
DLB$64.79-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim Condensed Consolidated Balance Sheets
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| March 29,2024 | September 29,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $709,535 | $745,364 |
| Restricted cash | 114,821 | 72,602 |
| Short-term investments | 115,863 | 139,148 |
| Accounts receivable, net of allowance for credit losses of $6,213 and $9,683 | 282,131 | 262,245 |
| Contract assets, net of allowance for credit losses of $105 and $138 | 243,170 | 182,130 |
| Inventories, net | 35,797 | 35,623 |
| Prepaid expenses and other current assets | 50,421 | 50,692 |
| Total current assets | 1,551,738 | 1,487,804 |
| Long-term investments | 127,973 | 97,812 |
| Property, plant, and equipment, net | 481,492 | 481,581 |
| Operating lease right-of-use assets | 43,057 | 40,199 |
| Intangible assets, net | 152,149 | 167,427 |
| Goodwill | 408,652 | 408,409 |
| Deferred taxes | 208,494 | 201,860 |
| Other non-current assets | 71,173 | 94,674 |
| Total assets | $3,044,728 | $2,979,766 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $19,727 | $20,925 |
| Accrued liabilities | 362,883 | 351,399 |
| Income taxes payable | 8,384 | 4,769 |
| Contract liabilities | 37,702 | 31,505 |
| Operating lease liabilities | 14,206 | 13,628 |
| Total current liabilities | 442,902 | 422,226 |
| Non-current contract liabilities | 36,453 | 39,997 |
| Non-current operating lease liabilities | 37,711 | 37,020 |
| Other non-current liabilities | 89,975 | 108,339 |
| Total liabilities | 607,041 | 607,582 |
| Stockholders’ equity: | ||
| Class A, $0.001 par value, one vote per share, 500,000,000 shares authorized: 59,737,770 shares issued and outstanding at March 29, 2024 and 59,673,633 at September 29, 2023 | 53 | 53 |
| Class B, $0.001 par value, ten votes per share, 500,000,000 shares authorized: 36,085,779 shares issued and outstanding at March 29, 2024 and 36,085,779 at September 29, 2023 | 41 | 41 |
| Retained earnings | 2,449,876 | 2,391,990 |
| Accumulated other comprehensive loss | (29,068) | (36,984) |
| Total stockholders’ equity – Dolby Laboratories, Inc. | 2,420,902 | 2,355,100 |
| Noncontrolling interest | 16,785 | 17,084 |
| Total stockholders’ equity | 2,437,687 | 2,372,184 |
| Total liabilities and stockholders’ equity | $3,044,728 | $2,979,766 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.